In Wake of Aduhelm Approval, Experts Debate the Utility of Surrogate Endpoints
November 2, 2021
The FDA’s controversial Aduhelm (aducanumab) accelerated approval in June has pointed a bright spotlight at the growing use of surrogate endpoints in clinical trials. Some experts are arguing that the benefits of using them outweigh the downsides, while others are arguing they should be used only as a “last resort” in drug and device trials.